Literature DB >> 14530859

Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery.

Christian Stocker1, Daniel J Penny, Christian P Brizard, Andrew D Cochrane, Rodrigo Soto, Lara S Shekerdemian.   

Abstract

OBJECTIVE: To investigate the acute effects of intravenous sildenafil on haemodynamics and oxygenation, and its interaction with inhaled nitric oxide (iNO) in infants at risk of pulmonary hypertension early after cardiac surgery.
DESIGN: Prospective, randomised trial.
SETTING: Paediatric intensive care unit of a children's hospital. PATIENTS AND PARTICIPANTS: Sixteen ventilated infants early after closure of ventricular or atrioventricular septal defects, were randomly assigned to one of two groups. The study was completed in 15 infants.
INTERVENTIONS: Studies were commenced within 7 h of separation from bypass. Seven infants received iNO (20 ppm) first, with the addition of intravenous sildenafil (0.35 mg/kg over 20 min) after 20 min. Eight infants received sildenafil first, iNO was added after 20 min. Vascular pressures, cardiac output and a blood gas were recorded at 0, 20 and 40 min. MEASUREMENTS AND
RESULTS: In infants receiving iNO first, iNO lowered the pulmonary vascular resistance index (PVRI) from 3.45 to 2.95 units (p=0.01); sildenafil further reduced PVRI to 2.45 units p<0.05). In those receiving sildenafil first, PVRI was reduced from 2.84 to 2.35 units (p<0.05) with sildenafil, and fell to 2.15 units (p=0.01) with the addition of iNO. In both groups, sildenafil reduced the systemic blood pressure and systemic vascular resistance (p<0.01) and worsened arterial oxygenation and the alveolar-arterial gradient (p<0.05).
CONCLUSION: Intravenous sildenafil augmented the pulmonary vasodilator effects of iNO in infants early after cardiac surgery. However, sildenafil produced systemic hypotension and impaired oxygenation, which was not improved by iNO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530859     DOI: 10.1007/s00134-003-2016-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  32 in total

1.  Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises.

Authors:  Andrew M Atz; Amy K Lefler; David L Fairbrother; Walter E Uber; Scott M Bradley
Journal:  J Thorac Cardiovasc Surg       Date:  2002-09       Impact factor: 5.209

2.  Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations.

Authors:  M C Seghaye; J Duchateau; J Bruniaux; S Demontoux; H Détruit; C Bosson; G Lecronier; E Mokhfi; A Serraf; C Planché
Journal:  Crit Care Med       Date:  1997-06       Impact factor: 7.598

3.  Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

Authors:  D Abrams; I Schulze-Neick; A G Magee
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

4.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group.

Authors:  R H Clark; T J Kueser; M W Walker; W M Southgate; J L Huckaby; J A Perez; B J Roy; M Keszler; J P Kinsella
Journal:  N Engl J Med       Date:  2000-02-17       Impact factor: 91.245

5.  Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.

Authors:  Lara S Shekerdemian; Hanne B Ravn; Daniel J Penny
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

6.  Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study.

Authors:  O I Miller; S F Tang; A Keech; N B Pigott; E Beller; D S Celermajer
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

7.  Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Authors:  Evangelos Michelakis; Wayne Tymchak; Dale Lien; Linda Webster; Kyoko Hashimoto; Stephen Archer
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

8.  Two-patch repair of complete atrioventricular septal defect in the first year of life. Results and sequential assessment of atrioventricular valve function.

Authors:  R G Weintraub; W J Brawn; A W Venables; R B Mee
Journal:  J Thorac Cardiovasc Surg       Date:  1990-02       Impact factor: 5.209

9.  Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics.

Authors:  D S Celermajer; S Cullen; J E Deanfield
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

10.  Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.

Authors:  D Walmrath; T Schneider; R Schermuly; H Olschewski; F Grimminger; W Seeger
Journal:  Am J Respir Crit Care Med       Date:  1996-03       Impact factor: 21.405

View more
  42 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

Review 2.  Year in review in intensive care medicine-2003. Part 3: intensive care unit organization, scoring, quality of life, ethics, neonatal and pediatrics, and experimental.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-26       Impact factor: 17.440

Review 3.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

Review 4.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

5.  Post-Extubation Inhaled Nitric Oxide Therapy via High-Flow Nasal Cannula After Fontan Procedure.

Authors:  Yuji Tominaga; Shigemitsu Iwai; Sanae Yamauchi; Miyako Kyogoku; Yosuke Kugo; Moyu Hasegawa; Futoshi Kayatani; Kunihiko Takahashi; Hisaaki Aoki; Muneyuki Takeuchi; Kazuya Tachibana; Hiroaki Kawata
Journal:  Pediatr Cardiol       Date:  2019-05-07       Impact factor: 1.655

Review 6.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Sildenafil exposure and hemodynamic effect after Fontan surgery.

Authors:  Robert D Tunks; Piers C A Barker; Daniel K Benjamin; Michael Cohen-Wolkowiez; Gregory A Fleming; Matthew Laughon; Jennifer S Li; Kevin D Hill
Journal:  Pediatr Crit Care Med       Date:  2014-01       Impact factor: 3.624

8.  Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.

Authors:  Peter M Mourani; Marci K Sontag; D Dunbar Ivy; Steven H Abman
Journal:  J Pediatr       Date:  2008-10-31       Impact factor: 4.406

9.  Postoperative use of oral sildenafil in pediatric patients with congenital heart disease.

Authors:  Ju Yeon Uhm; Won-Kyoung Jhang; Jeong-Jun Park; Dong-Man Seo; Sung-Cheol Yun; Tae-Jin Yun
Journal:  Pediatr Cardiol       Date:  2010-01-07       Impact factor: 1.655

10.  Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion.

Authors:  Balu Vaidyanathan
Journal:  Ann Pediatr Cardiol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.